Evidence map›Paper›PMID 25237200›Full record

ReviewBlood2014

Paroxysmal nocturnal hemoglobinuria.

Robert A Brodsky

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 302 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
302citing papers in PubMed, 4 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

302 citing papers in PubMed, 4 syntheses or guidelines pooled it, 609 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Article

242 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robert A BrodskyDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Johns Hopkins Medicine · US

Funding

THERAPEUTIC USE OF STEM CELLSP01CA070970 · NCI · JOHNS HOPKINS UNIVERSITY · PI CIVIN, CURT I · 1998 to 2012
$23.7M
NCI NIH HHS P01 CA070970NCI NIH HHS P01CA70970
6 · The paper itself

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias. The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH manifestations. GPI anchor protein deficiency is almost always due to somatic mutations in phosphatidylinositol glycan class A (PIGA), a gene involved in the first step of GPI anchor biosynthesis; however, alternative mutations that cause PNH have recently been discovered. In addition, hypomorphic germ-line PIGA mutations that do not cause PNH have been shown to be responsible for a condition known as multiple congenital anomalies-hypotonia-seizures syndrome 2. Eculizumab, a first-in-class monoclonal antibody that inhibits terminal complement, is the treatment of choice for patients with severe manifestations of PNH. Bone marrow transplantation remains the only cure for PNH but should be reserved for patients with suboptimal response to eculizumab.

Indexed as

Bone Marrow TransplantationGlycosylphosphatidylinositolsHemoglobinuria, ParoxysmalHumansMonitoring, PhysiologicMutationGlycosylphosphatidylinositols

Identifiers

PMID25237200
PMCPMC4215311
OpenAlexW1978700432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.